Ohio State Navbar

Clinical Trials


The talented faculty within the Division of Medical Oncology are proud to be a part of the Comprehensive Cancer Center Network  and one of only five centers in the nation that is approved for Phase I and Phase II clinical Trials. Our team  currently has numerous clinical trials open to accrual  focusing on cancers ranging from non-small cell lung cancer, pancreatic cancer, metastatic breast cancer, metastatic melanoma and much more.  If you are interested in learning more about our current clinical trials, please use the search feature for more information.

 

Current Clinical Trials

Below are a few of the recently opened cancer clinical trials available at Ohio State.

If you would like more information or are interested in referring a patient to one of these trials, click on the PI's name to generate a contact email, reply to this message or call The James Line at 1-800-293-5066.

Be sure to check out our NEW cancer clinical trials search tool by visiting cancer.osu.edu

Featured Trial:
Heme Malignancy and BMT
Phase II Open-Label Study to Investigate the Efficacy of Autologous EBV-Specific T-Cells for the Treatment of Patients With Aggressive Extranodal NK/T-Cell Lymphoma (ENKTCL)
OSU-14109 Pierluigi Porcu, MD

CNS Malignancy

Phase II, Multicenter, Open-Label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma
OSU-14066 (Vinay Puduvalli, MD)

Gastrointestinal

Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell-Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma
OSU-13024 (William Carson, MD)

Randomized Phase II Trial of Single-Agent MEK Inhibitor Trametinib (GSK1120212) vs. 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
SWOG-S1310 (Tony Bekaii-Saab, MD)

Phase II, Multicenter, Single-Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-Based Chemotherapy
OSU-14106 (Tony Bekaii-Saab, MD)

Phase II Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
OSU-14006 (Richard Goldberg, MD)

Phase Ib Clinical Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma
OSU-14146 (Tony Bekaii-Saab, MD)

Genitourinary

Phase I, Open-label, Multicenter, Dose-Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
OSU-14108 (Amir Mortazavi, MD)

Randomized, Open-Label, Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-Resistant Prostate Cancer (CRPC) Who Have Bone Metastases
OSU-13256 (J. Paul Monk, MD)

Gynecologic

Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK1120212) in
Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
GOG-0281 (David O'Malley, MD)

Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs. Combined Androgen Deprivation (LHRH analogue + Bicalutamide) in Metastatic Hormone-Sensitive Prostate Cancer
OSU-13239 (J. Paul Monk, MD)

Phase I Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
OSU-14154 (John Hays, MD, PhD)

Breast

Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A011202 (Doreen Agnese, MD)

Compassionate Use of ABT 888 for a Patient With Metastatic Breast Cancer
OSU-14241 (Maryam Lustberg, MD)

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
OSU-14043 (Robert Wesolowski, MD)

Phase I Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
NRG-BR001 (Jose Bazan, MD)

Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
OSU-13079 (Lisa Yee, MD)

Thoracic

Phase II Trial Combining Hypofractionated Radiation Boost With Conventionally Fractionated Chemoradiation in Locally Advanced Non-Small-Cell Lung Cancer Not Suitable for Surgery
OSU-14091 (Terrance Williams, MD, PhD)

Phase II/III Biomarker-Driven Master Protocol for Second-Line Therapy of Squamous Cell Lung Cancer (Screening Step)
SWOG-S1400 (Erin Bertino, MD)

Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI0639 as a Single Agent and in Combination Therapy in Adult Subjects With Advanced Solid Tumors, Including Small-Cell Lung Cancer
OSU-14044 (Erin Bertino, MD)

Phase I Study of Trametinib in Combination With Chemoradiation for Kras Mutant Non-Small-Cell Lung Cancer
OSU-14034 (Meng Welliver, MD)

Heme Malignancy and BMT 

Phase IB Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed/Refractory or Untreated CLL/SLL/PLL
OSU-14123 (Jennifer Woyach, MD)

Randomized, Open-Label, Phase II Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor  (KPT-330) vs. Specified Physicians Choice in Patients > 60 Years Old With Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
OSU-14047 (William Blum, MD)

Phase I, Open-Label, Dose-Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
OSU-14049 (Don Benson, MD, PhD)

Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixa for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs
OSU-14079 (Samantha Jaglowski, MD)

Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma
OSU-14148 (Kristie Blum, MD)

Head and Neck

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein-Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
NRG-HN001 (Dukagjin Blakaj, MD)

Randomized Phase II Trial for Patients With p16-Positive, Non-Smoking-Associated, Locoregionally advanced Oropharyngeal Cancer
NRG-HN002 (Maura Gillison, MD, PhD)

Melanoma

Randomized Phase II Trial of Intermittent vs. Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
SWOG-S1320 (Kari Kendra, MD, PhD)

Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High-Dose IL-2 vs. High-Dose IL-2 alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study
OSU-14083 (Thomas Olencki, DO)

Sarcoma

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma and Ewing/Ewing-like Sarcomas
OSU-14056 (David Liebner, MD)